Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Prodia Widyahusada Tbk (PRDA.JK)
IDR2,380.00
-10.00 (-0.42%)
ID JKT Healthcare Medical - Diagnostics & Research
Address
Prodia Tower 10430
Jakarta, JK, ID
Jakarta, JK, ID
CEO
Dewi Muliaty
Website
prodia.co.id
IPO
2016-12-07
ISIN ID1000138001
Description
PT Prodia Widyahusada Tbk provides clinical laboratory services in Indonesia. The company offers test services, such as genomic, laboratory, and non-laboratory tests, as well as test panels; doctor consultation and teleconsultation services; vaccines; home services; and research support services. It also engages in the operation of Prodia Health Care, a personalized medicine-based wellness clinic; and specialty clinics, including Prodia Children, Prodia Women, and Prodia Senior. The company was founded in 1973 and is headquartered in Jakarta Pusat, Indonesia. PT Prodia Widyahusada Tbk operates as a subsidiary of PT Prodia Utama.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
IDR2,380.00
-10.00 (-0.42%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
681.8K
Beta
-0.30
Float Shares
242.90M
Free Float %
27.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.80% | -0.39% | +4.55% | +6.30% | +9.52% | -8.33% | -55.61% | -39.04% | -61.67% | -61.67% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2,380.00
DCF (Unlevered)
15,740.95
+561.4%
DCF (Levered)
10,093.68
+324.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.39
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
A+
Overall Score
5 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+1.3% Q1'26: +3.8% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-21.2% Q1'26: +162.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+14.7% Q1'26: +16.7% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+10.0% ★ Q1'26: +4.6% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+10.7% ★ Q1'26: +4.2% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-2.9% ★ Q1'26: -5.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.04× ★ Q1'26: 0.06× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.36T
est: 1.35T (+0.8%)
|
1.47T
est: 1.48T (-1.0%)
|
1.60T
est: 1.60T (-0.1%)
|
1.74T
est: 1.79T (-2.5%)
|
1.87T
est: 1.74T (+7.8%)
|
2.65T
est: 2.63T (+1.0%)
|
2.18T
est: 2.21T (-1.4%)
|
2.22T
est: 2.19T (+1.4%)
|
2.25T
est: 2.28T (-1.1%)
|
2.28T
est: 2.28T (+0.1%)
|
2.35T
2.35T – 2.35T
+3.0% YoY
|
2.41T
2.41T – 2.41T
+2.8% YoY
|
| EBITDA |
182.65B
est: 364.80B (-49.9%)
|
272.71B
est: 400.72B (-31.9%)
|
311.36B
est: 433.08B (-28.1%)
|
357.08B
est: 484.13B (-26.2%)
|
490.77B
est: 470.03B (+4.4%)
|
948.89B
est: 710.20B (+33.6%)
|
629.26B
est: 598.34B (+5.2%)
|
478.95B
est: 569.45B (-15.9%)
|
515.61B
est: 591.88B (-12.9%)
|
475.65B
est: 592.47B (-19.7%)
|
610.33B
610.33B – 610.33B
+3.0% YoY
|
627.19B
627.19B – 627.19B
+2.8% YoY
|
| EBIT |
136.67B
est: 274.92B (-50.3%)
|
213.06B
est: 301.99B (-29.5%)
|
234.89B
est: 326.38B (-28.0%)
|
276.45B
est: 364.85B (-24.2%)
|
351.52B
est: 354.23B (-0.8%)
|
803.55B
est: 535.22B (+50.1%)
|
482.38B
est: 450.92B (+7.0%)
|
342.85B
est: 408.20B (-16.0%)
|
345.43B
est: 424.28B (-18.6%)
|
227.11B
est: 424.70B (-46.5%)
|
437.51B
437.51B – 437.51B
+3.0% YoY
|
449.59B
449.59B – 449.59B
+2.8% YoY
|
| Net Income |
88.13B
est: 78.49B (+12.3%)
|
150.80B
est: 128.17B (+17.7%)
|
175.45B
est: 161.19B (+8.8%)
|
210.26B
est: 189.12B (+11.2%)
|
268.75B
est: 210.38B (+27.7%)
|
623.23B
est: 639.11B (-2.5%)
|
371.65B
est: 408.77B (-9.1%)
|
259.87B
est: 220.11B (+18.1%)
|
270.20B
est: 232.90B (+16.0%)
|
206.79B
est: 224.25B (-7.8%)
|
260.56B
260.56B – 260.56B
+16.2% YoY
|
274.24B
274.24B – 274.24B
+5.3% YoY
|
| SGA |
34.00B
est: 282.67B (-88.0%)
|
285.45B
est: 310.50B (-8.1%)
|
303.53B
est: 335.57B (-9.5%)
|
337.78B
est: 375.13B (-10.0%)
|
267.94B
est: 364.21B (-26.4%)
|
345.79B
est: 550.30B (-37.2%)
|
316.12B
est: 463.62B (-31.8%)
|
962.88B
est: 567.63B (+69.6%)
|
442.62B
est: 589.99B (-25.0%)
|
889.66B
est: 590.58B (+50.6%)
|
608.38B
608.38B – 608.38B
+3.0% YoY
|
625.19B
625.19B – 625.19B
+2.8% YoY
|
| EPS |
115.85
est: 83.72 (+38.4%)
|
160.85
est: 136.72 (+17.7%)
|
187.15
est: 171.93 (+8.9%)
|
224.28
est: 201.73 (+11.2%)
|
286.66
est: 224.40 (+27.7%)
|
664.78
est: 681.72 (-2.5%)
|
396.42
est: 436.02 (-9.1%)
|
277.20
est: 241.89 (+14.6%)
|
288.21
est: 255.95 (+12.6%)
|
227.25
est: 246.44 (-7.8%)
|
286.33
286.33 – 286.33
+16.2% YoY
|
301.37
301.37 – 301.37
+5.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-26 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-25 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-22 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-21 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-20 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-18 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
363.20B
OE per share TTM
404.31
Owner's Yield
16.13%
Maintenance CapEx ratio
122.06%
Maint CapEx / Avg PPE
41.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
78.10M
Shares Outstanding
889.78M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andri Hidayat | Integrated Solutions & Diagnostic Director and Director | — | male |
| Dewi Muliaty | President Director | — | female |
| Ida Zuraida | People & Organizational Development Director and Director | — | female |
| Indriyanti Rafi Sukmawati | Commercial & Partnership Director and Director | — | female |
| Liana Kuswandi | President Director | — | female |
| Marina Eka Amalia | Finance and Sustainability Director, Head of Legal, Corporate Secretary & Director | — | female |
| Sri Paulani | Head of Internal Audit | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PRDA.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
